Shanxi Zhendong Pharmaceutical Working Capital to Net Assets Ratio
Shanxi Zhendong Pharmaceutical working capital to net assets ratio. Shanxi Zhendong Pharmaceutical (300158) has a Working Capital to Net Assets ratio of 49.6% as of September 2025. Working capital of CN¥1.80 Billion (current assets of CN¥2.64 Billion minus current liabilities of CN¥842.02 Million) is measured against net assets of CN¥3.63 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible equity quality of Shanxi Zhendong Pharmaceutical to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Shanxi Zhendong Pharmaceutical (2007–2024)
Working capital to net assets ratio of Shanxi Zhendong Pharmaceutical from 2007 to 2024. This chart shows how Shanxi Zhendong Pharmaceutical's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 49.6%, reflecting working capital of CN¥1.80 Billion against net assets of CN¥3.63 Billion CNY. See 300158 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Shanxi Zhendong Pharmaceutical Working Capital to Net Assets Ratio by Year (2007–2024)
Shanxi Zhendong Pharmaceutical working capital to net assets ratio by year from 2007 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Shanxi Zhendong Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Shanxi Zhendong Pharmaceutical total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 53.6% | CN¥1.96 Billion | CN¥3.66 Billion | CN¥3.22 Billion | CN¥1.26 Billion | ▼ -15.3 pp |
| 2023 | 68.9% | CN¥3.54 Billion | CN¥5.14 Billion | CN¥4.46 Billion | CN¥917.07 Million | ▼ -1.5 pp |
| 2022 | 70.3% | CN¥3.67 Billion | CN¥5.22 Billion | CN¥4.88 Billion | CN¥1.21 Billion | ▼ -11.9 pp |
| 2021 | 82.2% | CN¥6.62 Billion | CN¥8.05 Billion | CN¥8.42 Billion | CN¥1.80 Billion | ▲ +44.7 pp |
| 2020 | 37.5% | CN¥2.11 Billion | CN¥5.63 Billion | CN¥3.82 Billion | CN¥1.71 Billion | ▲ +3.2 pp |
| 2019 | 34.3% | CN¥1.87 Billion | CN¥5.44 Billion | CN¥2.95 Billion | CN¥1.08 Billion | ▲ +1.4 pp |
| 2018 | 32.9% | CN¥1.77 Billion | CN¥5.36 Billion | CN¥3.21 Billion | CN¥1.44 Billion | ▲ +2.0 pp |
| 2017 | 31.0% | CN¥1.72 Billion | CN¥5.56 Billion | CN¥3.44 Billion | CN¥1.72 Billion | ▲ +2.9 pp |
| 2016 | 28.0% | CN¥1.48 Billion | CN¥5.27 Billion | CN¥2.75 Billion | CN¥1.27 Billion | ▲ +34.3 pp |
| 2015 | -6.3% | CN¥-126.99 Million | CN¥2.03 Billion | CN¥1.74 Billion | CN¥1.87 Billion | ▼ -32.9 pp |
| 2014 | 26.6% | CN¥524.07 Million | CN¥1.97 Billion | CN¥1.27 Billion | CN¥747.89 Million | ▼ -2.4 pp |
| 2013 | 29.0% | CN¥568.74 Million | CN¥1.96 Billion | CN¥1.27 Billion | CN¥704.09 Million | ▼ -6.4 pp |
| 2012 | 35.4% | CN¥672.73 Million | CN¥1.90 Billion | CN¥1.29 Billion | CN¥619.51 Million | ▼ -23.5 pp |
| 2011 | 58.9% | CN¥1.09 Billion | CN¥1.86 Billion | CN¥1.46 Billion | CN¥369.09 Million | ▼ -22.0 pp |
| 2010 | 80.9% | CN¥1.44 Billion | CN¥1.78 Billion | CN¥1.81 Billion | CN¥371.48 Million | ▲ +66.7 pp |
| 2009 | 14.2% | CN¥50.90 Million | CN¥359.31 Million | CN¥328.56 Million | CN¥277.66 Million | ▲ +12.0 pp |
| 2008 | 2.1% | CN¥5.68 Million | CN¥266.72 Million | CN¥226.63 Million | CN¥220.95 Million | ▲ +41.4 pp |
| 2007 | -39.2% | CN¥-69.19 Million | CN¥176.42 Million | CN¥214.82 Million | CN¥284.01 Million | — |